Pepticom Ltd., one of BioGiv’s innovative resident companies, is excited about the ongoing transformation in the pharmaceutical industry, driven by Artificial Intelligence (AI). In a recent post, Pepticom's CEO shared insights from the J.P. Morgan Healthcare Investment Conference, highlighting the growing impact of AI on drug discovery and the future of healthcare.
In a piece published by Paul Hudson, CEO of Sanofi, on the World Economic Forum website, the article outlines how AI-driven drug discovery could contribute to 30% of new drug discoveries by 2025. This revolutionary shift is set to accelerate drug development timelines by 25-50%, especially in preclinical stages. The article also touches on enhancing patient engagement through digital tools, funding growth through mergers, and leveraging AI for innovative healthcare solutions.
At Pepticom, they are leveraging AI to design novel peptide drugs, extending the chemical space and developing therapies for previously untreatable diseases. This approach is cutting drug discovery timelines and costs, enabling faster identification of effective therapies with greater efficiency.
With AI leading the charge, Pepticom is on the cutting edge of the future of drug discovery and healthcare innovation.
Read the full article by Paul Hudson on the World Economic Forum: Link to article